Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.2
4.6
Journals
Bioengineering
Special Issues
Recent Advances of Protein Therapeutics
share announcement

Recent Advances of Protein Therapeutics

A special issue of Bioengineering (ISSN 2306-5354). This special issue belongs to the section "Biochemical Engineering".

Deadline for manuscript submissions: closed (20 September 2023) | Viewed by 3205

Special Issue Editor

Dr. Zhilei Chen

E-Mail Website
Guest Editor
Microbial Pathogenesis and Immunology, Texas A and M Health Science Center, Bryan, TX, USA
Interests: protein therapeutic; oral therapeutic; protein engineering

Special Issue Information

Dear Colleagues,

Protein-based therapeutics have recently evolved into a large class of drug molecules that encompass both natural and engineered recombinant proteins. Proteins exhibit unique advantages and limitations as therapeutics. This Special Issue will focus on the development of protein therapeutics against new drug targets, as well as technologies for protein therapeutic engineering.

  1. Antibodies and synthetic biotherapeutic engineering;
  2. Purification and industrial production of therapeutic proteins;
  3. Formulation of and delivery technologies for protein therapeutics;
  4. New display technologies for therapeutic protein engineering;
  5. Evolvability and developability of antibodies and synthetic scaffolds;
  6. Protein–drug conjugates;
  7. Computational protein design and engineering;
  8. Natural and synthetic protein scaffold engineering.

Dr. Zhilei Chen
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Bioengineering is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

13 pages, 2202 KiB  
Review
Recent Advances in Optically Controlled PROTAC
by Muzi Ouyang, Ying Feng, Hui Chen, Yanping Liu, Chunyan Tan and Ying Tan
Bioengineering 2023, 10(12), 1368; https://doi.org/10.3390/bioengineering10121368 - 28 Nov 2023
Cited by 1 | Viewed by 1283
Abstract
Proteolysis-targeting chimera (PROTAC) technology is a groundbreaking therapeutic approach with significant clinical potential for degrading disease-inducing proteins within targeted cells. However, challenges related to insufficient target selectivity raise concerns about PROTAC toxicity toward normal cells. To address this issue, researchers are modifying PROTACs [...] Read more.
Proteolysis-targeting chimera (PROTAC) technology is a groundbreaking therapeutic approach with significant clinical potential for degrading disease-inducing proteins within targeted cells. However, challenges related to insufficient target selectivity raise concerns about PROTAC toxicity toward normal cells. To address this issue, researchers are modifying PROTACs using various approaches to enhance their target specificity. This review highlights innovative optically controlled PROTACs as anti-cancer therapies currently used in clinical practice and explores the challenges associated with their efficacy and safety. The development of optically controlled PROTACs holds the potential to significantly expand the clinical applicability of PROTAC-based technology within the realm of drug discovery. Full article
(This article belongs to the Special Issue Recent Advances of Protein Therapeutics)
►▼ Show Figures

Figure 1

16 pages, 1197 KiB  
Review
Methods for Engineering Binders to Multi-Pass Membrane Proteins
by Benjamin Thomas, Karuppiah Chockalingam and Zhilei Chen
Bioengineering 2023, 10(12), 1351; https://doi.org/10.3390/bioengineering10121351 - 24 Nov 2023
Viewed by 1566
Abstract
Numerous potential drug targets, including G-protein-coupled receptors and ion channel proteins, reside on the cell surface as multi-pass membrane proteins. Unfortunately, despite advances in engineering technologies, engineering biologics against multi-pass membrane proteins remains a formidable task. In this review, we focus on the [...] Read more.
Numerous potential drug targets, including G-protein-coupled receptors and ion channel proteins, reside on the cell surface as multi-pass membrane proteins. Unfortunately, despite advances in engineering technologies, engineering biologics against multi-pass membrane proteins remains a formidable task. In this review, we focus on the different methods used to prepare/present multi-pass transmembrane proteins for engineering target-specific biologics such as antibodies, nanobodies and synthetic scaffold proteins. The engineered biologics exhibit high specificity and affinity, and have broad applications as therapeutics, probes for cell staining and chaperones for promoting protein crystallization. We primarily cover publications on this topic from the past 10 years, with a focus on the different formats of multi-pass transmembrane proteins. Finally, the remaining challenges facing this field and new technologies developed to overcome a number of obstacles are discussed. Full article
(This article belongs to the Special Issue Recent Advances of Protein Therapeutics)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop